Jefferies Remains a Buy on Elevance Health (ELV)
Jefferies analyst maintained a Buy rating on Elevance Health today and set a price target of $395.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In addition to Jefferies, Elevance Health also received a Buy from Wells Fargo’s Stephen Baxter in a report issued today. However, on the same day, TipRanks – OpenAI reiterated a Hold rating on Elevance Health (NYSE: ELV).
Based on Elevance Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $49.31 billion and a net profit of $547 million. In comparison, last year the company earned a revenue of $45.44 billion and had a net profit of $418 million
Read More on ELV:
Disclaimer & DisclosureReport an Issue
- Elevance Health price target lowered to $391 from $424 at Wells Fargo
- Elevance Health price target lowered to $393 from $404 at Barclays
- Elevance Health price target lowered to $400 from $425 at UBS
- Elevance Health price target raised to $332 from $320 at Deutsche Bank
- Elevance Health price target lowered to $396 from $414 at Guggenheim
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.